The Pharma Data

AUGUST 18, 2020

The investigational therapy has obviously caught the eye of BMS, and it was confirmed that the company intends to exercise its newly bought rights to push the drug forward in oncology and haematology.

Protein 52

Protein Sales Drugs 52

Delveinsight

FEBRUARY 9, 2021

Breyanzi, BMS’ Blood Cancer CAR-T Therapy Receives FDA Nod. Breyanzi will come with a price tag of USD 410,300 wholesale price, said the company, justifying it after taking into consideration several factors including medical and clinical value, patient value, and societal value.

FDA Approval 52

FDA Approval Marketing Research Protein 52

pharmaphorum

JANUARY 5, 2021

Bristol-Myers Squibb’s CLTA4 inhibitor Yervoy (ipilimumab) is already in use for some cancers, including NSCLC in combination with BMS’ PD-1 drug Opdivo (nivolumab), but has been held up by tolerability issues. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

MARCH 27, 2022

While drugs like Blenrep and teclistamab need to be administered intermittently, CAR-Ts are complex, “one and done” therapies made from a patient’s own immune cells, with a hefty price tag to match. In the US, Abecma has a list price of around $420,00, while J&J has set its therapy a little higher at $465,000.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

XTalks

MARCH 22, 2023

In 2019, BMS acquired Celgene in a $74 billion deal. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more. Increased competition from generics and biosimilars has also prompted widespread change within the industry.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97